News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Progenics Pharmaceuticals, Inc. (PGNX) Falls After Two Deaths In Cancer Drug Trial


1/30/2014 7:40:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Progenics Pharmaceuticals Inc. (PGNX) fell the most in 14 months after a study summary showed two patients died of sepsis in a trial of the company’s experimental prostate cancer treatment. Progenics tumbled 19 percent to $5.04 at 12:11 p.m. New York time, after losing as much as 20 percent for its biggest intraday drop since November 2012. The Tarrytown, New York-based company’s stock had doubled in the 12 months through yesterday.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg
Read at Seeking Alpha

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES